683 Capital Management LLC Purchases Shares of 290,000 Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

683 Capital Management LLC purchased a new stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 290,000 shares of the biotechnology company's stock, valued at approximately $1,447,000. 683 Capital Management LLC owned approximately 0.49% of Aldeyra Therapeutics as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of ALDX. Hsbc Holdings PLC purchased a new stake in shares of Aldeyra Therapeutics during the 4th quarter valued at $52,000. Catalyst Funds Management Pty Ltd increased its position in Aldeyra Therapeutics by 2,083.3% during the 4th quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company's stock valued at $65,000 after buying an additional 12,500 shares in the last quarter. Regal Investment Advisors LLC purchased a new stake in Aldeyra Therapeutics in the fourth quarter valued at about $66,000. Walleye Capital LLC purchased a new stake in shares of Aldeyra Therapeutics during the fourth quarter worth about $68,000. Finally, U.S. Capital Wealth Advisors LLC acquired a new position in shares of Aldeyra Therapeutics during the fourth quarter valued at about $69,000. Institutional investors own 59.71% of the company's stock.

Insider Buying and Selling

In related news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the company's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total value of $4,828,000.00. Following the completion of the transaction, the insider now owns 5,875,851 shares of the company's stock, valued at approximately $8,343,708.42. This represents a 36.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 8.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ALDX has been the subject of a number of recent analyst reports. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research note on Friday, April 4th. BTIG Research reduced their target price on Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Monday, April 7th.

Aldeyra Therapeutics Stock Performance

Shares of NASDAQ ALDX opened at $2.71 on Friday. The stock has a market cap of $162.32 million, a price-to-earnings ratio of -2.88 and a beta of 0.94. Aldeyra Therapeutics, Inc has a 12 month low of $1.14 and a 12 month high of $7.20. The company has a 50 day simple moving average of $4.45 and a two-hundred day simple moving average of $4.98. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last posted its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.30). As a group, analysts predict that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.

Want to see what other hedge funds are holding ALDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.